Multiple Myeloma and Other Plasma Cell Neoplasms

  • Meletios A. Dimopoulos
  • Thierry Facon
  • Evangelos Terpos

Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Table of contents

  1. Front Matter
    Pages i-vi
  2. Malin Hultcrantz, Gareth J. Morgan, Ola Landgren
    Pages 1-15
  3. S. Vincent Rajkumar, Rafael Fonseca, Jesus F. San Miguel
    Pages 17-28
  4. P. Sonneveld, H. Einsele, A. M. Brioli, M. Cavo
    Pages 29-60
  5. Eileen Mary Boyle, Thierry Facon, Maria Victoria Mateos, Antonio Palumbo
    Pages 61-71
  6. Jacob P. Laubach, Philippe Moreau, Meletios A. Dimopoulos, Paul G. Richardson
    Pages 73-96
  7. Noemi Puig, Carmela Palladino, Bruno Paiva, Marco Ladetto
    Pages 97-109
  8. Evangelos Terpos, Nikolaos Kanellias, Noopur Raje
    Pages 111-140
  9. Heinz Ludwig, Meletios-Athanasios Dimopoulos, Evangelos Terpos
    Pages 141-156
  10. Morie A. Gertz, Laura Rosinol, Joan Bladé
    Pages 157-175
  11. Dimitrios C. Ziogas, Angela Dispenzieri, Evangelos Terpos
    Pages 177-189
  12. Steven P. Treon, Giampaolo Merlini, Meletios A. Dimopoulos
    Pages 191-220
  13. Efstathios Kastritis, Ashutosh Wechalekar, Giampaolo Merlini
    Pages 221-245

About this book


This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. 


Extramedullary Plasmacytoma Monoclonal Gammopathy of Undetermined Significance Multiple Myeloma Plasma Cell Leukemia Primary Systemic Amyloidosis Waldenstrom's Macroglobulinemia

Editors and affiliations

  • Meletios A. Dimopoulos
    • 1
  • Thierry Facon
    • 2
  • Evangelos Terpos
    • 3
  1. 1.School of MedicineNational and Kapodistrian University of AthensAthensGreece
  2. 2.Service des Maladies du SangCHRU Lille Hôpital Claude HuriezLilleFrance
  3. 3.School of MedicineNational and Kapodistrian University of AthensAthensGreece

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing Switzerland 2018
  • Publisher Name Springer, Cham
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-3-319-25584-2
  • Online ISBN 978-3-319-25586-6
  • Series Print ISSN 2197-9766
  • Series Online ISSN 2197-9774
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology